Skip to main content
Premium Trial:

Request an Annual Quote

Cambrex Buys Immortalized Cell Line Assets from XCellsyz

NEW YORK, Jan. 18 (GenomeWeb News) - Cambrex subsidiary Cambrex Bio Science Wokingham will buy conditionally immortalized cell lines and related intellectual property and equipment from British biotech Xcellsyz, Cambrex said today.


Financial terms of the deal were not disclosed.


Last week, Cambrex signed a worldwide licensing pact with Geron that will see it develop its own immortalized cell lines for distribution using Geron's human telomerase reverse transcriptase technology. XCellsyz last year had signed a similar agreement for Geron's telomerase technology, which it used to develop its own immortalized cell lines.


Cambrex said it will use the recently acquired technologies to immortalize a broad set of cell types, which it will sell to researchers for a variety of applications, including cell-based high-throughput drug screening and toxicity testing.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.